An Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)

Running, not enrolling · Phase 1

Conditions studied: Healthy Participants, Pharmacokinetic Study

In brief

This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants

Key facts

Study ID

NCT07361354

Run by

Angitia Incorporated Limited

People needed

28

Starts

2026-01-05

Expected to finish

2026-09-01

Last updated by the study team

2026-07-08

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy males or females, aged 18 to 65 years
• 25-hydroxyvitamin D ≥30 ng/mL and agree to taking calcium and vitamin D supplements during the study
• Meet the criteria for Japanese, Chinese, or Caucasian ethnicity

You may not qualify if…

• Participating or have participated in another clinical trial within the past 6 months
• Any bone fracture within the past 6 months
• History of myocardial infarction or stroke within the past 12 months
• Malignancy within the past 5 years
• Current hyper- or hypocalcemia
• Pregnant or breastfeeding women, or women planning to become pregnant during the study

Where it is running

• Los Angeles EPCU — Glendale, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.